1. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. (January 2022) Authors: Rubin, David T; Dotan, Iris; DuVall, Aaron; Bouhnik, Yoram; Radford-Smith, Graham; Higgins, Peter D R; Mishkin, Daniel S; Arrisi, Pablo; Scalori, Astrid; Oh, Young S; Tole, Swati; Chai, Akiko; Chamberlain-James, Kirsten; Lacey, Stuart; McBride, Jacqueline; Panés, Julian; Abdulkhakov, Rustem; Abu ... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 1(2022) Page Start: 17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. (February 2022) Authors: Peyrin-Biroulet, Laurent; Hart, Ailsa; Bossuyt, Peter; Long, Millie; Allez, Matthieu; Juillerat, Pascal; Armuzzi, Alessandro; Loftus, Edward V; Ostad-Saffari, Elham; Scalori, Astrid; Oh, Young S; Tole, Swati; Chai, Akiko; Pulley, Jennifer; Lacey, Stuart; Sandborn, William J; Aguilar, Humberto; Ah... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 2(2022) Page Start: 128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗